The merger creates a Goliath. What they have done is created the best of the best.

This is a theme that I think investors are missing, because as tech and retail companies continue to warn about profit shortfalls, there are no revisions in the drug area.

The fundamentals for big pharmaceutical firms are fine. Cash is fine to support growth, and earnings are meeting the targets. I think investors are taking some of that for granted and ignoring it.

One-hundred-ten years of history, great diversity, lots of new earnings drivers and I just became a grandpa -- twins. And I'm buying J&J, Pfizer and Warner for their future college funds.